Acumen Pharmaceuticals (ABOS) vs BioStem Technologies (BSEM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
BioStem Technologies (BSEM) has outperformed Acumen Pharmaceuticals (ABOS) over the past year, losing 84.0% versus a loss of 88.1%. Over five years, BSEM leads with a -55.9% price change compared with -97.7% for ABOS. Acumen Pharmaceuticals is the larger company by market cap ($13.5 million vs $12.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABOS | BSEM |
|---|---|---|
| Share price | $0.1865 | $0.6351 |
| Market cap | $13.49M | $12.18M |
| 1-day change | -3.52% | -10.23% |
| YTD return | -91.16% | -83.33% |
| 1-year return | -88.12% | -83.98% |
| 5-year return | -97.74% | -55.90% |
| P/E ratio (TTM) | — | 0.72 |
| Forward P/E | — | 2.19 |
| EPS (TTM) | $-1.55 | $0.88 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-121.33M | — |
| 52-week high | $3.60 | $8.40 |
| 52-week low | $0.16 | $0.5347 |
| Distance from 52-week high | -94.82% | -92.44% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +3975.07% | +1002.19% |
| Average volume | 2.73M | 194.93K |
| Shares outstanding | 72.33M | 19.18M |
| Employees | 60 | 73 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Acumen Pharmaceuticals
ABOS stock →Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 60 employees
About BioStem Technologies
BSEM stock →BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 73 employees
ABOS vs BSEM FAQ
Which is bigger, Acumen Pharmaceuticals or BioStem Technologies?
Acumen Pharmaceuticals (ABOS) is larger, with a market capitalization of $13.49M compared with $12.18M for BioStem Technologies (BSEM).
Which stock has performed better over the past year, ABOS or BSEM?
BSEM returned -83.98% over the past 12 months, compared with -88.12% for ABOS (price return, excluding dividends). Past performance does not predict future results.
Are Acumen Pharmaceuticals and BioStem Technologies in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.